Close
GS1 Global Healthcare Conference 2026
LiGHT 2026

BD Receives FDA Approval for the BD FocalPoint™ GS Imaging System

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

WebMD Ignite Ruby Transforms Healthcare Marketing...

WebMD Ignite has announced the launch of WebMD Ignite...

Mayo Clinic Study Validates AI Tool...

Researchers at Mayo Clinic have found that an artificial...

MHRA Outlines New Agenda for AI...

The United Kingdom’s Medicines and Healthcare products Regulatory Agency...
BD Diagnostics, a segment of BD announced that it received U.S. FDA Premarket Approval (PMA) for the BD FocalPoint™ GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath™ Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.

BD Diagnostics, a segment of BD announced that it received U.S. FDA Premarket Approval (PMA) for the BD FocalPoint™ GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath™ Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.

Vincent A. Forlenza, BD Executive Vice President, The launch of the BD FocalPoint™ GS System represents a key milestone in our effort to expand BD’s presence in cancer diagnostics . It is the first in a series of innovative products aimed at improving the detection and clinical management of cancer, resulting from our TriPath acquisition.

The key to detecting cervical cancer early is regular Pap testing. However, limitations exist with current technologies. Approximately one-third of Pap smear false negatives can be attributed to screening and interpretive errors in which abnormal cells are incorrectly classified.

Wayne Brinster, Vice President and General Manager, BD Diagnostics – TriPath said, Our clinical trial results give us confidence that the BD FocalPoint™ GS Imaging System will provide cytology labs with the advanced tool they need to improve cervical cancer detection and enhance their productivity. It demonstrates BD’s commitment to providing innovative, world-class products and services for the oncology market that help improve patient outcomes by offering clinicians better tools to detect and manage disease

Never miss a healthcare headline

Healthcare moves fast – stay on top of it with our must - read briefings.

  • The top hospital and healthcare stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments transforming global healthcare management

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Mayo Clinic Study Validates AI Tool DEXI for Skin Lesion Assessment

Researchers at Mayo Clinic have found that an artificial...

MHRA Outlines New Agenda for AI Medical Devices at AdvaMed

The United Kingdom’s Medicines and Healthcare products Regulatory Agency...

UK Confirms Indefinite Use of CE Marked Medical Devices

The United Kingdom government has officially confirmed the indefinite...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »